

Cancer Research UK's Early Diagnosis Conference 2024

4 – 5 June 2024

The Eastside Rooms, Birmingham



#CRUKEDConference24

Contents

Click on the headings below to navigate to a specific section of the programme.

3	Welcome
4	Day 1: Programme
8	Day 2: Programme
12	Speakers
35	Early Career Researchers
39	People affected by cancer
46	Early diagnosis research posters
51	Conference planning team

Welcome

Welcome to Cancer Research UK's sixth biennial Early Diagnosis Conference! We are delighted to be welcoming you all in-person for the first time since 2019.

We've come a long way since our first conference in 2011, though the goal of the conference remains the same: to encourage dialogue, collaboration and action between researchers, health professionals and policymakers that will drive earlier diagnosis of cancer. Fitting with this, 'Driving Evidence into Practice' is the theme for this year's conference.

It's been fantastic to see the continued interest in the event from the community. As proof, we've seen the highest number of abstract submissions ever and we saw places sell out in record time. We're thrilled to have a programme that is jam-packed with high-quality presentations, posters and workshops that showcase the latest behavioural, epidemiological, clinical and health systems research across the cancer diagnostic pathway.

As outlined in our recent report, 'Longer, better lives: A manifesto for cancer research and care', which launched in November 2023, one of our key missions is to diagnose cancers earlier. Unfortunately, late-stage diagnosis of cancer is still a significant problem in the UK, with almost half of cancers diagnosed at a late stage, where treatment options are limited, and survival is poor. However, we have made significant advances in our understanding of how to reduce late-stage cancer, and this year's conference aims to present the collective, deepening knowledge in the field. We'll also highlight how crucial research and innovation are to filling evidence gaps and responding to health system needs. What continues to be clear is that there is no one intervention or solution to achieving earlier diagnosis. It's a complex problem that needs to be tackled through a range of interventions across all levels of the system.

Working closely with this community, we're committed to engaging across the pathway, driving evidence-based change and preparing health systems for the translation of new research into practice. This is crucial to achieving early diagnosis ambitions and to improving the lives of people affected by cancer.

Thank you for attending and contributing to the conference. We hope that you enjoy everything the event has to offer.

Sam Harrison

Cancer Research UK's Early Diagnosis Conference Lead

Head of Strategic Evidence and Lead for the International Cancer Benchmarking Partnership, Cancer Research UK



Programme

Tuesday 4 June

08:30 – 09:30 **Registration**

09:30 – 09:45 **Welcome:** Naser Turabi
📍 Affinity 2, Ground floor

09:45 – 11:00 **Strategic approaches to early diagnosis**
Exploring how each UK nation is addressing late-stage diagnoses and how they're assessing progress, joined by Professor Sir Mike Richards

Chair: Dr Owen Jackson

Professor Tom Crosby, Nicola Barnstaple and Dr Tomas Adell

Reflections: Professor Sir Mike Richards CBE

📍 Affinity 2, Ground floor

11:00 – 11:10 **Patient speaker:** Michael Anderson

11:10 – 11:30 **Break**

11:30 – 12:40 **Improving understanding of risk associated with clinical features in primary care including symptoms and investigations**

Chair: Professor Brian Nicholson

Cancer incidence and competing mortality risk following 15 presenting symptoms in primary care: a population-based cohort study using electronic healthcare records – Dr Matt Barclay

Developing and implementing age- and sex-specific thresholds for platelet count for cancer detection in primary care: a cohort study in English, Canadian, and Australian primary care data – Associate Professor Sarah Bailey

Blood test trends for cancer detection in patients presenting with unexpected weight loss in primary care: a diagnostic accuracy, longitudinal cohort study – Dr Pradeep Virdee

The diagnostic performance of PSA for the detection of prostate cancer in primary care: a population-based cohort study – Dr Garth Funston

📍 Affinity 2, Ground floor

12:40 – 13:40

Lunch, posters and networking

📍 Affinity 1, Ground floor

CRUK early detection and diagnosis research strategy and funding opportunities

Chairs: Dr Joanna Janus and Dr Talisia Quallo, CRUK

This is an optional, informal session taking place over lunch that will introduce CRUK's research strategy for early detection and diagnosis research and our funding opportunities in this area. It will also provide an opportunity for networking.

📍 Belmont 1 and 2, Ground floor

13:40 – 14:45

Parallel sessions

Early Career Researcher spotlight

Chair: Professor Fiona Walter

Distal adenomas and hyperplastic polyps in relation to future proximal colon cancer risk – Dr Rhea Harewood

Identification of patients at high risk of lung cancer in primary care – Melissa Barlow

User and developer views on using Artificial Intelligence technologies to facilitate the early diagnosis of skin cancers in primary care settings: a qualitative study – Dr Owain Jones

It is hard to beat FIT: Machine learning models that combine the faecal immunochemical test (FIT) with routinely collected data did not outperform FIT for colorectal cancer detection in 31,964 patients – Andres Tamm

Protocol of a Health Economic Evaluation of a novel Prostate Cancer Rapid Diagnosis Pathway (PROSTAD) – Esra Erdem

📍 Affinity 2, Ground floor

Workshop:

Equitably improving cancer detection: four key considerations when implementing innovations

Chair: Dr Anna Dowrick

This workshop will draw on implementation science and contemporary case studies to explore key considerations for sustainable implementation of cancer detection initiatives within health systems and clinical practice.

📍 Ashted, First floor

Workshop:
Implementing Lynch syndrome surveillance pathways

Chairs: Lucy McLaughlin and James Harris

This workshop will bring together delegates to discuss the development and implementation of Lynch syndrome surveillance pathways, focusing on demand and activity modelling challenges, and the transition from a pilot to a sustainably commissioned service.

📍 Belmont 3 and 4, Ground floor

14:45 – 15:05

Break

15:05 – 16:15

Parallel sessions

Understanding and developing interventions to address inequalities in cancer

Chair: Dr Pawan Randev

Understanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis – Dr Yin Zhou

Symptom interpretation and help seeking in male and female participants with depression and/or anxiety: a vignette study on bowel cancer symptoms – Dr Bettina Friedrich

Developing a tool to improve patient experience and engagement with their recommended lung cancer care pathway: Exploring the impact of distance and disadvantage in urban and rural settings – Dr Samuel Cooke and Dr Lucy Mitchinson

Improving breast screening for People With Learning Disabilities – Dr Mansi Tara

📍 Affinity 2, Ground floor

Improving early diagnosis of bowel cancer

Chair: Dr Katherine Elliott

Estimating the effect of screen detection on colorectal cancer survival correcting for time bias: a result from the Netherlands National Colorectal Cancer Screening – Joy Li

Co-producing practice guidelines and research recommendations to support early diagnosis of colorectal cancer in the community pharmacy – Professor Christian Von Wagner

Developing a chatbot to support participation in the NHS bowel cancer screening programme – Dr Jazzine Smith

Patients' and healthcare practitioners' experiences of symptomatic FIT: findings from the COLOFIT interview study – Dr Adam Biran and Dr Christina Dobson

📍 Belmont 1 and 2, Ground floor

16:15 – 16:30

Break

16:30 – 17:45

Cancer screening landscape

Diving into the current state of play, what's coming down the line and what's needed to prepare for the future

Chair: Naser Turabi

Intermediate endpoints as sufficient surrogates for cancer-specific mortality in cancer screening trials: a systematic review and meta-analysis – Professor Sian Taylor-Phillips

Attitudes to self-sampling as a choice in future cervical screening – Professor Jo Waller

Results of the Yorkshire Kidney Screening Trial, a feasibility study of adding abdominal non-contrast CT scanning to screen for kidney cancer and other abdominal pathology to CT-based screening for lung cancer – Dr Juliet Usher-Smith

Underdiagnosis in breast screening – time to change – Professor Fiona Gilbert

📍 Affinity 2, Ground floor

17:45 – 17:50

Wrap up: Naser Turabi

19:15

Conference dinner

📍 Affinity 2, Ground floor

Programme

Wednesday 5 June

08:30 – 08:50 **Registration**

08:50 – 09:00 **Welcome:** Naser Turabi
📍 Affinity 2, Ground floor

09:00 – 10:05 **Innovation in cancer**
Showcasing approaches that support the translation and adoption of innovations to improve cancer outcomes

Chair: Professor Richard Gilbertson

Target Product Profiles: stimulating innovation on fit-for-purpose early cancer diagnostics – Professor Bethany Shinkins

Improving lung cancer diagnostic pathway in Wales: QUICDNA – Dr Margherita Carucci

Public receptiveness to risk-based innovations – Professor Jo Waller and Dr Rebecca Dennison

📍 Affinity 2, Ground floor

10:05 – 10:20 **Break**

10:20 – 11:10 **Parallel sessions**

Spotlight on activity to understand and improve public awareness and help-seeking

Chair: Professor Kate Hamilton-West

Help-seeking behaviour and barriers to help-seeking in the UK public: findings from the Cancer Awareness Measure survey – Dr Victoria Whitelock

Developing a new approach to symptom awareness campaigns through behaviour change – Andy Glyde and Phillipa Williams

Utilizing targeted Facebook advertisements to enhance engagement with a lung cancer symptom assessment line service – Dr Savita Shanbhag

📍 Affinity 2, Ground floor

Identifying areas for improvement in diagnostic pathways and their timeliness

Chair: Jon Shelton

Long-waiters: analysis of patients waiting over 104 days from urgent suspected cancer referral to first cancer treatment – Lorna Wills

Characteristics of cancer patients diagnosed via the A&E route: a focus on prostate cancer – Dr Ruth Swann

Analysis of the Faster Diagnosis Standard performance for patients with cancer – Dr Fahmina Fardus-Reid

📍 Belmont 1 and 2, Ground floor

Spotlighting innovative approaches to diagnostic research and implementation

Chair: Professor Jared Torkington

How should we include ethnicity in prediction models that guide clinical decision making? A multidisciplinary reflection on potential and risk – Dr Tanvi Rai

Liquid biopsies are more acceptable for colorectal cancer detection in underserved groups: results of a qualitative mixed methods study – Professor Dean Harris

BRCA-gene testing in breast cancer patients: how can we do better with limited clinical resources? A North Thames mainstreaming pilot using the BRCA-DIRECT pathway – Bethany Torr

📍 Ashted, First floor

11:10 – 12:15

Parallel sessions

Early Career Researcher spotlight

Chair: Professor Peter Murchie

Does health literacy have a role to play in the early diagnosis of head and neck cancer? – Jennifer Deane

A systematic literature review of the barriers to breast cancer screening and the effectiveness of interventions to address them, experienced by women of Black African and Black Caribbean descent in the UK – Anietie Aliu

Symptomatic presentation and barriers to help-seeking amongst rural residents with symptoms of bowel cancer – Emily Haworth

The impact of rurality on symptom clustering: a population-based analysis – Dr Adegoke Alabi

Societal views on using risk-based innovations to inform cancer screening and referral policies: findings from three community juries –

Dr Rebecca Dennison

📍 Affinity 2, Ground floor

Workshop:

Drawing on behavioural science and health systems insights to improve timely help-seeking for possible cancer symptoms

Chairs: CRUK and Dr Maja Nikšić

This workshop will examine approaches to address barriers to help-seeking, considering opportunities and mechanisms for translating evidence into real world impact and reducing health inequalities.

📍 Belmont 1 and 2, Ground floor

Workshop:

Optimising non-specific symptom pathways

Chair: Dr Georgia Black

This workshop will bring together delegates to discuss the latest evidence and insights on non-specific symptom pathways, providing an opportunity to network, share learning, and collaborate to further optimise the pathways.

📍 Ashted, First floor

Workshop:

Target Product Profiles: prioritising innovation in early cancer diagnosis

Chairs: Professor Bethany Shinkins and Dr Jac Dinnes

This interactive workshop will explore factors that can aid in identifying and prioritising innovations to address unmet need in the early diagnosis of cancer.

📍 Belmont 3 and 4, Ground floor

12:15 – 13:15

Lunch, posters and networking

📍 Affinity 2, Ground floor

13:15 – 14:20

Inequalities in cancer diagnosis

Bringing behavioural and epidemiological insights together to understand and address inequalities

Chairs: Professor Bernard Rachet and Professor Katriina Whitaker

Pre-existing physical and mental health morbidities, healthcare use and stage at cancer diagnosis: a population-based study of two cancers – Dr Helen Fowler

PPIE perspectives on sex- and ethnicity-specific barriers to timely female cancer diagnosis – Melissa Barlow, Auguster Gold, Celia Butler and Yusra Siddiqui

📍 Affinity 2, Ground floor

14:20 – 14:35

Break

14:35 – 15:50

Identifying opportunities for timelier diagnosis

Chair: Professor Georgios Lyratzopoulos

A diagnostic window of opportunity: seven studies examining primary healthcare utilisation before the diagnosis of different cancers in both UK and Australia – Dr Meena Rafiq

How patient resistance to investigation of possible cancer symptoms occurs within GP consultations and implications for consultation outcomes: an analyses of GP consultation video data – Dr Lucy Brindle

What determines GPs' inclination to refer patients with suspected cancer? A vignette-based survey – Dr Olga Kostopoulou

Advice after urgent suspected cancer referral when cancer is not found: What do patients want and what do they receive? – Professor Suzanne Scott

📍 Affinity 2, Ground floor

15:50 – 16:10

Wrap up and prize giving: Naser Turabi

📍 Affinity 2, Ground floor

16:10

Conference close

Speakers



Dr Tomas Adell

Director of Elective Care and Cancer Policy, Department of Health, Northern Ireland

Tomas Adell, PhD is the Director of Elective Care and Cancer Policy in the Department of Health in Northern Ireland. He is responsible for the implementation of the Cancer Strategy in Northern Ireland, and is the policy lead for cancer services and elective care services. Tomas co-chairs the Cancer Programme Board which oversees cancer provisions in Northern Ireland.



Michael Anderson

Patient speaker

Michael was born in Sunderland in 1959 and studied art history in the UK and Germany. He's worked in a variety of social care jobs before becoming a project manager and then moving to policy and political advice. His retirement plans to travel the globe were cut short by a cancer diagnosis in 2020. Since then, he has worked with the North Central London Cancer Alliance and, more recently, was appointed as a Patient and Public Voice partner with the NHS England Cancer Programme. Michael jointly runs an online help group for people living with anal cancer and recently formed a charity to promote awareness of anal cancer called Bottom Line.



Associate Professor Sarah Bailey

University of Exeter

Sarah is Associate Professor of Primary Care Diagnostics at the University of Exeter. She leads a portfolio of research focussed on cancer diagnosis in primary care, including the development and implementation of new strategies for symptomatic patients. She has published practice-changing research on the use of blood-based markers of cancer, the use of faecal immunochemical tests for symptomatic patients, and the integration of genetic risk scores into suspected cancer pathways. Sarah holds an NIHR Advanced Fellowship and has attracted over £6m of funding from organisations including the NIHR and Cancer Research UK.



Dr Matt Barclay

Statistician, University College London

Matt is a statistician who has been working with population-based cancer data since 2012. He currently works in the Epidemiology of Cancer Healthcare and Outcomes (ECHO) group at UCL, supported by a CRUK ACED Pathway Award fellowship. His research interests primarily involve use of large, routinely-collected, health datasets to examine cancer care pathways, with a current focus on risk of cancer in symptomatic patients presenting in primary care. He has a PhD in Public Health and Primary Care from the University of Cambridge, an MSc in Statistics with Medical Applications, and an MMath in Mathematics from the University of Durham.



Nicola Barnstaple

Associate National Director – Cancer Performance and Early Diagnosis, National Centre for Sustainable Delivery, Scotland

Nicola provides leadership in the development and delivery of the NHS Scotland cancer strategy earlier and faster diagnosis workstreams in her role and also holds an SLA with Scottish Government. She has a career dedicated to cancer and health policy across the voluntary sector, local government and NHS in Scotland, at national and local levels. Nicola is passionate about using her own cancer diagnosis as motivation to improve patient outcomes and to deliver change.



Dr Adam Biran

Research Associate, Population Health Sciences Institute, Newcastle University

Adam Biran is a Research Associate in the Population Health Sciences Institute at Newcastle University. He is a mixed methods social science researcher whose interests include cancer survivorship, health behaviours, behaviour change and evaluation.



Dr Georgia Black

Health Services Researcher, Wolfson Institute of Population Health

Georgia's research has two main foci: patient safety in primary care and across cancer pathways; and the effect of socioeconomic inequalities and specifically exclusion from healthcare. She uses patient safety approaches in conjunction with psychological theory across a programme of work including primary care cancer referrals, interpreted consultations in primary care, diagnostic uncertainty and safety netting, and cancer pathway evaluation and development. In 2019, Georgia was awarded a Postdoctoral Fellowship by The Health Improvement Studies (THIS) Institute around diagnostic safety culture in non-specific symptom pathways for cancer (previously Rapid Diagnostic Centres), using an ethnographic case study design.



Dr Lucy Brindle

Associate Professor, University of Southampton

Lucy's research combines symptom epidemiology with health communication research to develop innovative solutions to improve early cancer diagnosis. Her previous research has integrated health communication with symptomatic diagnosis studies to improve cancer prediction models; current research is investigating patient-GP communication about 'low but not no' cancer risk in primary care consultations. This research is improving our understanding of how communication about safety-netting advice and investigations might be optimised to enhance shared decision-making and enable earlier cancer diagnosis. Lucy also teaches Diagnostic Reasoning Skills to healthcare professionals.



Celia Butler

PPIE Representative

Celia is a PPIE representative for the University of Exeter. She is an experienced engineer who is passionate about combining her lived experience and technology to provide a new perspective and help create innovative solutions which make a real difference to people's lives.



Dr Margherita Carucci

Senior Trial Manager, Cardiff University

Margherita has long term experience in the design and management of national and international Phase II and III multicentre cancer trials (both CTIMPs and non-CTIMPs). She is currently the Study Lead of two biomarker studies in lung and ovarian cancer, a recently funded CRUK study on cancer skin prevention, and two CTIMPs in breast cancer.




Reanna Clune

Research Assistant, University of Cambridge

Reanna Clune is a Research Assistant at the University of Cambridge. She holds a Master's degree in Health Psychology from the University of Galway, Ireland and her research interests focus on women's health, particularly in the areas of cancer prevention, early detection and diagnosis.

Reanna joined the Department of Public Health and Primary Care as a research assistant on the CRUK funded "Ribbon's" project, which studied public receptiveness to risk-based approaches for cancer prevention and early diagnosis. She also contributed to the NIHR funded "STRAT-BCS" project, which aimed to understand public preferences regarding risk stratification for colorectal cancer screening.

Currently, Reanna is a research assistant in the Department of Psychology working on the "CanRisk in Secondary Care Breast Services" project. This project seeks to develop a pathway to enable the integration of multifactorial risk assessment in secondary care breast services.



Dr Samuel Cooke

Research Associate, Lincoln Institute for Rural and Coastal Health

Samuel's research interests are primarily concerned with exploring the intersectionality between cancer inequalities and rural and coastal environments. His previous work has focused on exploring and understanding the experiences of people living with cancer who reside in rural and coastal areas through qualitative and systematic review methodologies, as well as developing platforms for cancer patients and carers to share their lived cancer experiences. Samuel is currently working on a Cancer Research UK funded study that aims to explore the impact of distance and disadvantage on lung cancer care and outcomes in Lincolnshire and North East London.



Professor Tom Crosby

National Cancer Clinical Director for Wales

Tom is a Consultant Oncologist in Velindre Cancer Centre, specialising in Upper GI cancer since 2008. As clinical lead for the Wales Cancer Network Tom led the development of the Cancer Service Improvement Plan 2022-25 and the Wales Cancer Network Board's prioritisation programme including the development of Cancer Prevention, Early Diagnosis, Person Centred Care and Cancer Information work streams. He leads a priority initiative in Wales: the Single Cancer Pathway which looks to transform patient pathways from referral, through diagnosis and treatment.

Tom has recently been recognised for his service to cancer services in Wales and the UK with the award of an honorary Professorship by Cardiff University and an OBE in the New Year's Honours list and is now the National Clinical Director of Cancer for Wales.



Dr Christina Dobson

Senior Research Associate, Population Health Sciences Institute, Newcastle University

Christina is a Senior Research Associate in the Population Health Sciences Institute at Newcastle University. She is a qualitative researcher whose interests are in early diagnosis, cancer inequalities, patient engagement and experience, and co-design of interventions to address cancer inequalities.



Anna Dowrick

Senior Researcher, University of Oxford

Anna is a Senior Researcher in the Cancer Group and Medical Sociology and Health Experiences Research Group in the Nuffield Department of Primary Care Health Sciences. She is an interdisciplinary social scientist, spanning the fields of medical sociology, medical anthropology and science and technology studies. Her research explores injustice through the lens of health and illness and how this can be addressed through thoughtful approaches to implementing improvements in cancer detection.



Dr Jac Dinnes

Senior Research Fellow, University of Birmingham

Jac is a Senior Research Fellow at the University of Birmingham. She is a methodologist with a long-standing interest in the evaluation of diagnostic tests and an international reputation for excellence in this work. She has a large and sustained portfolio of systematic reviews and publications from methodological projects, recently co-leading the Cochrane Covid-19 Diagnostic Test Accuracy Group. Jac has been an advisory group member for the development of international reporting guidelines and quality assessment tools for test accuracy studies. Ongoing interests include the development of practical tools to guide the efficient development and evaluation of diagnostic tests, with a particular emphasis on early identification of ways in which a test might create benefit in a given clinical pathway.



Dr Katherine Elliott

Clinical Director, Northern Cancer Alliance
Cancer Research UK GP

Katie holds several roles, including Primary Care Clinical Director in Northern Cancer Alliance, CRUK GP and a general practitioner in Northumbria primary care.

Katie is passionate about improving outcomes for people affected by cancer through improving cancer services. Working closely with a range of stakeholders across primary and secondary care, community and third sector, she has catalysed and delivered regional programmes and advised on national efforts that focus on improving outcomes, reducing inequalities and drive better patient experiences.



Dr Fahmina Fardus-Reid

Data Research and Analysis manager, Cancer Research UK

Fahmina Fardus-Reid, Ph.D, is a Data Research and Analysis Manager at Cancer Research UK. Her research interests include cancer epidemiology and research into the early diagnosis and treatment of cancer.



Dr Helen Fowler

Research Fellow, University College London

Helen is a Research Fellow in cancer epidemiology in the Epidemiology of Cancer Healthcare and Outcomes research group at University College London. Her current work examines the influence of pre-existing morbidities on the diagnostic process of cancer. She has previously worked with Cancer Council Queensland in Australia, researching survival and psychosocial outcomes among women diagnosed with breast cancer in Queensland, and worked at the London School of Hygiene and Tropical Medicine, as part of a Cancer Research UK funded research programme investigating inequalities in cancer outcomes.

Helen holds a PhD in Epidemiology and Population Health from the London School of Hygiene and Tropical Medicine, and a MSc in Epidemiology and Biostatistics from the University of Leeds.



Dr Bettina Friedrich

Research Psychologist, University College London

Bettina's research focuses on mental health, mental health stigma, health communication and service evaluation. Furthermore, she is interested in improving ways of how research can be effectively translated into policy recommendations. Bettina has completed her undergraduate degree in Psychology and Musicology at the Universität des Saarlandes (Germany) with a focus on Clinical Psychology, Media/Communication/Organisational Psychology and Cross-Cultural Psychology. She received a full-time studentship from the European Commission to do a PhD in Perceptual Psychology at the University of Glasgow. She has worked since then at University California San Diego, King's College London, Julius-Maximilians-Universität of Würzburg, and University of Sydney. In addition to her academic research, she has worked in psychiatric units and with mental health groups and policy makers (UK and abroad) who are tackling mental health related stigma and discrimination.



Dr Garth Funston

GP and Clinical Senior Lecturer in Primary Care Research,
Wolfson Institute of Population Health

Garth is a GP and Clinical Senior Lecturer in Primary Care Cancer Research at the Wolfson Institute of Population Health, where he co-leads the Cancer Early Diagnosis Unit. His research focuses on diagnostic test evaluation and the development and validation of prediction models using large healthcare datasets, with the aim of improving cancer detection in primary care.

Following medical training at St Andrews and Cambridge, Garth undertook clinical academic training in Manchester. He completed a Cancer Research UK funded PhD at the University of Cambridge, which focused on evaluating the ovarian cancer biomarker CA125 and developing the Ovatoools ovarian cancer prediction model for use in primary care. In 2021 he was awarded the World Ovarian Cancer Coalition Transformational Research Prize for his work. Garth currently leads a portfolio of charity and NIHR funded studies evaluating diagnostic tests and prediction models for ovarian, lung, prostate and upper gastro-intestinal cancers.



Professor Fiona Gilbert

Head of Department of Radiology, University of Cambridge

Fiona is focused on imaging techniques relating to breast cancer and oncology. She works in Addenbrookes Hospital and is part of the Cambridge Breast Unit which delivers screening to Cambridge & Huntingdon. She evaluates new imaging technology and is currently working on artificial intelligence in imaging to detect cancer, biomarkers to predict cancer and response to neoadjuvant therapy, novel imaging techniques such as sodium imaging with MRI and assessing different imaging tools to detect cancer in women with dense breasts.

She is a regular speaker at international Radiology conferences and was awarded Honorary membership of Radiological Society of North America in 2019, Honorary fellowship of the American College of Radiologists, the Gold Medal from the European Society of Radiology and fellowship of the Royal Society of Edinburgh in 2021 and fellowship of the Academy of Medical Sciences. She is immediate past President of the European Society of Breast Imaging.



Professor Richard Gilbertson

Head of Department of Oncology, University of Cambridge

Richard trained as a paediatric oncologist in the UK before moving in 2000 to St Jude Children's Research Hospital in the USA, where he served as Scientific and Comprehensive Cancer Centre Director, Executive Vice President and Lillian R Cannon Endowed Chair. In August 2015, he moved back to England where he is Li Ka Shing Chair of Oncology and Head of Department of Oncology at the University of Cambridge, Director of the Cancer Research UK Cambridge Centre and Senior Group Leader at the Cancer Research UK Cambridge Institute. His laboratory research is focused on understanding the link between normal development and the origins of cancer, particularly brain tumours. He is a Fellow of the Royal Society (FRS), Fellow of the Academy of Medical Sciences UK (FMedSci) and a member of the European Molecular Biology Organisation (EMBO).



Andy Glyde

Early Diagnosis Campaign Strategy Lead, Bowel Cancer UK

Andy is responsible for overseeing the charity's early diagnosis programme. This includes the development and delivery of a new major behaviour change campaign focused on bowel cancer symptoms and targeting people who are least likely to present to the GP, which is launching in May 2024. Andy has over 15 years experience in the charity sector, including at Cancer Research UK, Breast Cancer Care, Age UK and RNID, working in strategic communications, policy and public affairs. He was previously a Vice Chair of the Wales Cancer Alliance, a Co-Chair of the Obesity Alliance Cymru, and a trustee for Endometriosis UK for over six years.



Auguster Gold

PPI Representative

Auguster is a PPI representative of the Black African Community. She is a graduate of Health and Social care who lost her mother to cancer some 23 years ago. Auguster is happy to bring her lived experience to help sponsor new innovations that may bring new positive solutions.



Professor Kate Hamilton-West

Head of Social and Behavioural Research, Cancer Research UK

Kate is Head of Social and Behavioural Research at Cancer Research UK. She is a Chartered Psychologist, HCPC Registered Health Psychologist, Associate Fellow of the British Psychological Society, Fellow of the Higher Education Academy and Honorary Chair in the Centre for Health Services Studies at the University of Kent. Kate has worked in behavioural science and health services research for more than two decades, including roles across academia, NHS, the charity sector, and industry. Her work focuses on developing, implementing, and evaluating interventions, services, and programmes to improve outcomes for people living with long-term conditions. This includes research and innovation projects in cancer, diabetes, COPD, CHD, dementia, stroke, MS, depression, anxiety, and physical disabilities, as well as work focusing on health behaviours, stress and burnout in health professionals, mindfulness and social prescribing.



Professor Dean Harris

Consultant Colorectal Surgeon, Swansea Bay University Health Board

Dean subspecialises in advanced rectal cancer. He is Lead Clinician of the Colorectal Cancer MDT and clinical lead for the Wales Cancer Industry Forum. He is on the NHS Clinical Entrepreneur Programme since 2020 fuelling his interest in MedTech innovation.

In 2013 he became an honorary clinical professor in Swansea University Medical School with research interests in early detection of cancer and personalised cancer treatment, and has won over £2M in academic funding towards this.

He is co-founder and clinical director of CanSense, a Swansea University spin-out company, translating a reagent-free colorectal cancer serum diagnostic for the NHS to address cancer inequalities. CanSense won the St David Award for Science and Technology (2023), Wales Start-up of the year award for MedTech (2021) and the Institute of Physics Lee Lucas Award for Healthcare in 2021.



James Harris

Project Manager, North Central London Cancer Alliance

An experienced senior healthcare manager, James plays a key role at the North Central London Cancer Alliance, leading innovative, strategic programmes of work within the gastrointestinal cancer pathways. Encompassing LGI, UGI, Non-Site-Specific Symptoms, and HPB, his responsibilities span both primary and secondary care, consistently delivering results that demonstrably benefit patients and the wider healthcare system. Prior to this, James was an operational manager at a large tertiary NHS Trust, where he led medical, surgical and cancer specialties.



Dr Owen Jackson

Director of Policy, Cancer Research UK

Owen joined Cancer Research UK in 2022 from the UK's Government Office for Science, where he was Deputy Director for Global Issues and Opportunities, responsible for developing science and research policy with the Government Chief Scientific Adviser.

Owen has a wealth of experience in strategy, policy development and programme delivery from over a decade of experience across the Civil Service. Previous roles include serving as Deputy Director at both the Geospatial Commission and the Northern Ireland Office, and Private Secretary to the National Security Adviser. He has held several roles operating at the interface between science, research and policy, is a Policy Fellow at the Royal Academy of Engineering and was the Cabinet Office's first Head of Profession for Science and Engineering. His research background is in microbiology.



Dr Olga Kostopoulou

Reader in Medical Decision Making, Imperial College London

Olga, PhD, is a Reader in Medical Decision Making at Imperial College London. She is an experimental psychologist studying decision making in healthcare with extensive experience in the study of clinical reasoning, early diagnosis, decision support, and the impact of risk-prediction algorithms on clinical judgement. She has held 3 project grants from CRUK. She uses mixed research methods with a preference for quantitative approaches. Olga was the 2021-22 President of the Society for Medical Decision Making and is Associate Editor of Medical Decision Making and Frontiers in Cognition.



Joy Li

Statistician, Queen Mary University

Joy is a statistician by training, educated at the London School of Hygiene and Tropical Medicine, with a PhD from Queen Mary, University of London. Most of their work focuses on screening, prevention, and early detection of cancer, primarily bowel and breast cancers. Their PhD focused on estimating the impact of using a multi-threshold FIT regimen in bowel cancer screening. Joy has also been involved in work evaluating the impact of various invitation strategies on attendance in the NHS Breast Screening Programme, and work in collaboration with NIHR North Arc Thames, to "improve breast cancer outcomes whilst reducing inequalities" for patients in catchment area of NHS Barts' Trust.



Professor Georgios Lyratzopoulos

Professor of Cancer Epidemiology, University College London


Georgios leads UCL's Epidemiology of Cancer Healthcare and Outcomes (ECHO) Group. He co-directs the NIHR Policy Research Unit on Cancer Awareness, Screening and Early Diagnosis (2024-2029), and has previously held fellowship awards by Cancer Research UK and NIHR. He was the cancer epidemiology member of the 2015 NICE Guidelines Development Group leading to the publication of NG12 (suspecting cancer in primary care). Empirical or conceptual work that he has led has been cited in key national or international policy documents, including national Cancer Strategies, WHO reports, and the Cancer Research UK Early Detection and Diagnosis of Cancer Roadmap. In 2016 Georgios was awarded the Cancer Research UK Future Leader Prize, which recognises individuals who have demonstrated world-leading potential within their first ten post-doctoral years, being the first epidemiologist to be given the Prize.



Lucy McLaughlin

Head of Cancer Commissioning, North Central London Cancer Alliance

Lucy is dedicated and results-driven healthcare leader with a proven track record in senior-level strategic healthcare roles. She is an effective communicator and collaborator with a strong commitment to integrity, innovation, and leadership. She is skilled in change management and driving system transformation; robust commissioning and performance management expertise; consummate in delivering positive outcomes.



Dr Lucy Mitchinson

Research Fellow in Behavioral Science, Wolfson Institute of Population Health

Lucy is a mixed-methods researcher with an interest in health systems and health inequality. Her work in recent years has focused on cancer diagnosis and treatment pathways. Her previous work involved conducting vignette surveys to explore which characteristics affect GP cancer referrals, rapid research into care delivery during health emergencies, and in-depth qualitative interviews with hospice staff and patients with life-limiting illnesses. She completed her PhD in the Marie Curie Palliative Care Research Department of University College London.



Professor Peter Murchie

Professor of Primary Care, Institute of Applied Health Sciences,
University of Aberdeen

Peter trained in medicine at the University of Aberdeen, graduating in 1994. He completed vocational training in general practice in Northeast Scotland before embarking upon a career in academic general practice through a Cancer Research UK Primary Care Oncology Fellowship. He is currently Professor of Primary Care and lead of the Academic Primary Care Research Group, within the Institute of Applied Health Sciences University of Aberdeen. He leads a research programme which uses clinical data to pursue two main aims: first to better understand the cancer diagnostic pathway within primary care, and second, to improve community-based cancer survivorship care. He maintains a foothold in daytime and out-of-hours general practice in Northeast Scotland.



Professor Brian Nicholson

Associate Professor, Nuffield Department of Primary Care Health Sciences,
University of Oxford

Brian's academic interests include cancer, global health, and evidence-based diagnosis. His research aims to improve the diagnostic process for patients with symptoms of cancer. This work focuses on understanding symptoms, appropriate test use, and developing clinical pathways. He leads the departmental Cancer Theme that conducts research in four main areas: health records data; implementation science; diagnostic reasoning; and clinical trials and prospective studies. He is Early Detection lead for the CRUK Oxford Cancer Centre investigating community-based multi-cancer early detection testing. He co-led SYMPLIFY1 investigating the performance of GRAIL's Multi-Cancer Early Detection test in symptomatic patients referred for urgent cancer investigation. He is an NHS GP in Oxford City.



Dr Maja Nikšić

Senior Epidemiologist, University of Kent

Maja is a cancer epidemiologist, with a strong background in medical statistics and psychology. She is an experienced quantitative and mixed methods researcher, with extensive experience in research design, survey development, analysing large data sets and linking different data bases. Her main interests are understanding socio-economic inequalities in cancer outcomes, improving health prevention interventions and public cancer symptom awareness, and investigating patterns of comorbidities. Based at the University of Kent, Maja is currently co-PI on a study aimed at applying social and behavioural research to enhance cancer prevention, diagnosis, screening, and treatment, funded by Cancer Research UK.



Professor Bernard Rachet

Professor of Cancer Epidemiology,
London School of Hygiene and Tropical Medicine

Bernard is a medical doctor by training and a cancer epidemiologist with extensive research experience into inequalities in cancer care and outcomes in England and other parts of the world.



Dr Meena Rafiq

Academic GP and Senior Clinical Research Fellow,
University College London (UCL) and the University of Melbourne

Meena is an Academic GP and Senior Clinical Research Fellow at University College London (UCL) and the University of Melbourne. She is supported by a CRUK International Alliance for Cancer Early Detection (ACED) Pathway Award. She has a specialist interest in research using linked primary care Electronic Health Records to improve early cancer diagnosis, with a particular focus on identifying early markers of underlying cancer using data from GP blood tests. Alongside working as a GP in Australia and the UK, she has a PhD in Primary Care Early Cancer Diagnosis, an MSc in Epidemiology, and expertise in conducting 'big data' research using a number of Primary Care datasets worldwide.



Dr Tanvi Rai

Senior Researcher, University of Oxford


Tanvi is a mixed methods senior researcher based at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. She has a PhD in public health and an interdisciplinary and international background that spans across public health and applied social sciences. She has a strong interest in health inequalities and the need to embed social justice principles across all health research and healthcare delivery. Her research so far has been about social and structural determinants of health, inclusive research methods and practices, maternal and sexual health, the organisation and delivery of cancer services, public health communication, as well as studies involving socially-sensitive health topics and working with socially marginalised populations.



Dr Pawan Randev

Cancer Research UK GP

Pawan is a GP Cancer Lead for the East Midlands Cancer Alliance and East Midlands Cancer Network. He has over 20 years' experience of educating doctors and nurses to provide better quality care, and has a particular interest in education for primary care teams around cancer. His professional interests include communication skills training and creating sustainable service improvements in primary care and public health. He works closely with stakeholders across the third sector, and is a CRUK GP where he advises and drives action particularly on cancer early diagnosis and screening.



Professor Sir Mike Richards CBE

CRUK Trustee and Chair of the UK National Screening Committee

Mike was an academic cancer physician specialising largely in breast cancer before being appointed as England's first National Cancer Director in 1999. After 13 years in that role he was appointed as the first Chief inspector of Hospitals at the Care Quality Commission, where he led the development and implementation of a new approach to inspecting, rating and regulating hospitals, mental health, community and ambulance services.

Since retiring in 2017 he has led reviews of screening and diagnostic services in the NHS on behalf of government and NHS England, which he is now working to see implemented. He chairs the UK National Screening Committee, which advises all four countries on screening programmes for cancer and other conditions.



Professor Suzanne Scott

Professor of Health Psychology and Early Cancer Diagnosis,
Wolfson Institute of Population Health

Suzanne is Professor of Health Psychology and Early Cancer Diagnosis at the Wolfson Institute of Population Health, Queen Mary University of London, where she is co-lead of the Centre for Cancer Screening, Prevention and Early Diagnosis. She is the behavioural science lead on several international collaborations including an NIHR Global Health Group on timely diagnosis of breast, cervical and colorectal cancer in Sub-Saharan Africa (www.awacan.online), and the CanDetect programme on detection of upper gastrointestinal cancer through the development of a multi-cancer early detection platform (www.candetect.org). The primary focus of Professor Scott's research is on symptom perception, cancer awareness and pathways to diagnosis and involves using psychological theory to design and evaluate interventions to encourage timely healthcare use and investigation for symptoms of cancer.



Dr Savita Shanbhag

GP Cancer Lead, Hywel Dda University Health Board

Savita's role includes promoting early diagnosis in patients with cancer and improving communication between Primary and Secondary Care. Savita has experience in leading Research and Innovation projects in the Health Board, including the successful launch of the Rapid Diagnosis Clinic (RDC) for vague symptoms in 2021, and the award-winning lung cancer symptom assessment line (LUMEN) project in 2022. She has been a co-investigator in various research and innovation projects, represents Primary Care views on oncology pathways at Health Board and Wales-wide meetings. Savita has recently been awarded Emerging Researcher Award by Health and Care Research Wales. Savita is experienced in leading and managing projects that involve changes to cancer pathways.



Dr Yusra Siddiqui

PPIE Representative

Yusra is joining this conference as a PPIE representative of the Asian community with lived experience of cancer diagnosis for her mother. She is also a Lecturer at the University of Exeter, with specialisms in prostate cancer biology and pedagogical interests centred around inclusive education in biosciences.



Jon Shelton

Head of Cancer Intelligence, Cancer Research UK

Jon's team generate data-driven evidence across cancer epidemiology, prevention, early diagnosis and treatment. Their work is used by CRUK and other organisations to drive improvement across the cancer pathway. Jon has over 15 years' experience of working with clinicians, academics and patients to produce evidence from cancer data, and has particular interest in inequalities and building collaborations with other organisations to pool skills and knowledge. He is passionate about the importance of research, using health data, and CRUK's role in providing patients, public and policymakers with the highest-quality evidence so that together we can prevent more cancers and improve outcomes.



Professor Bethany Shinkins

Professor of Health Economics, Diagnosis and Screening, University of Warwick

Bethany works on a large portfolio of applied test evaluation projects, including RCTs, analyses of routinely collected data, and economic modelling studies across a wide range of clinical diseases. She also undertakes reviews and evidence synthesis on the clinical and cost-effectiveness of medical tests for the NIHR Evidence Synthesis Programme on behalf of a range of policy makers, including the National Institute for Health and Care Excellence (NICE), and sits on the UK National Screening Committee. She is particularly interested in improving the methodology used to evaluate diagnostic and screening tests and the role that Target Product Profiles (TPPs) can play in focusing innovation and research efforts on fit-for-purpose diagnostics.



Dr Jazzine Smith

Research Fellow, University College London

Jazzine is a Research Fellow at University College London, and her primary research focuses on developing an innovative chatbot for the NHS Bowel Cancer Screening Programme. With a PhD in Psychology, she is motivated to transform healthcare technology through digital health research. Jazzine has contributed to diverse digital health products aimed at improving healthcare accessibility and quality, such as enhancing hearing health and supporting cancer survivors within the NHS. Her expertise lies in user engagement and behavioural change theories and she is committed to enhancing user experiences and outcomes.



Dr Ruth Swann

Senior Analyst, Cancer Research UK

Ruth is a senior analyst working on the Cancer Research UK – NHS Digital partnership. A focus of her work is understanding the patient pathway through primary care to cancer diagnosis using data from the National Cancer Diagnosis Audit and linked Cancer registry data.



Dr Mansi Tara

Health Promotion Lead,
North London and Central and East London Breast Screening Services

Mansi is a public health professional with over a decade of experience in healthcare. She is the Health Promotion lead at the North, Central and East London breast screening service leading a team to improve breast screening uptake and reducing health inequalities by improving equity of access for different population groups. She is a dentist by training, holds an MSc. in Public Health from the London School of Hygiene and Tropical Medicine and a Project Management Professional certificate. Prior to working in screening, Mansi led the strategy and programmes for a global charity aiming to improve safety of surgery and anaesthesia in low resource settings. She is passionate about health equity and empowering communities to access care they are entitled to.



Professor Sian Taylor-Phillips

Professor of Population Health, University of Warwick

Sian leads Warwick Screening, a team of expert researchers delivering evidence synthesis to directly support national policy decision-making. They specialise in evaluation of screening programmes and medical tests. Sian is especially interested in international research optimising the methods of evidence synthesis, working collaboratively with national policy-makers. She is also a member of the UK National Screening Committee and chairs their Research and Methodology Group, which advises the four UK Governments on research priorities, research gaps and methodology in screening. Sian holds an NIHR Research Professorship focused on methods of evaluating screening programmes, and synthesising evidence for policy-makers.



Professor Jared Torkington

Clinical Director, Moondance Cancer Initiative

Jared trained in medicine at St Mary's Hospital in London, and underwent surgical training in both London and Wales. Jared's clinical interests are all aspects of coloproctology and colonoscopy, as well as colorectal cancer and surgery. He is now a Consultant Colorectal Surgeon at the University Hospital of Wales in Cardiff, and President of The Association of Coloproctology of Great Britain and Ireland. As well as working as a surgeon, Jared is also clinical director of the Moondance Cancer Initiative, providing clinical leadership to its portfolio of grant investments and projects.



Bethany Torr

Scientific Programme Manager, Institute of Cancer Research

In addition to her role, Beth is a part-time PhD student within Professor Clare Turnbull's team in the Division of Genetics and Epidemiology. She also has an honorary contract within the Cancer Genetics Unit at the Royal Marsden NHS Foundation Trust. Having previously studied Genetics and Science Communication, with experience working in cancer patient advocacy and NHS research governance, the current focus of her work is cancer susceptibility genetics. Working as a Programme Manager on the 5-year, CRUK-funded catalyst award, CanGene-CanVar, aiming to generate and collate better evidence on cancer susceptibility risk and management, and translating this into routine clinical care. Beth is also completing a part-time PhD on the CRUK-funded BRCA-DIRECT study. The study (2020 – 2023) aimed to evaluate the feasibility and acceptability of a novel, digital pathway, integrated into NHS breast oncology clinics, to enable expansion of germline genetic testing.



Naser Turabi

Director of Evidence and Implementation, Cancer Research UK

Naser is Director of Evidence and Implementation at Cancer Research UK, where he leads the Strategic Evidence, Cancer Intelligence, Social and Behavioural Research, and Health Systems Engagement teams. His role is to accelerate the adoption of innovation and reduce inequalities in access to best practice care. He joined CRUK from North Central London Cancer Alliance where he was Managing Director. Previously he held a number of management roles in the NHS covering strategy, operations and transformation. He started his career in social research and public sector consultancy.



Professor Juliet Usher-Smith

Assistant Professor of General Practice, University of Cambridge

In addition to her role at the University of Cambridge, Juliet is a GP and NIHR Advanced Fellow. She was previously a CRUK Prevention Fellow. Her research focuses on implementation of risk-stratification within cancer screening programmes, including the societal, psychological and behavioural aspects associated with risk-based screening and risk-based innovations. Her current work includes research on strategies for implementation of risk-stratification into bowel cancer screening and proactive breast cancer risk assessment within primary care, a series of projects on the public receptiveness to risk-based innovations and she co-led the Yorkshire Kidney Screening Trial, the first study to assess the feasibility of incorporating an additional abdominal CT-scan within risk-based lung cancer screening programmes.



Professor Jo Waller

Professor of Cancer Behavioural Science, Wolfson Institute of Population Health

Jo is Professor Cancer Behavioural Science in the Wolfson Institute of Population Health, Queen Mary University of London. She co-leads the Screening, Prevention and Epidemiology Unit in the Centre for Cancer Screening, Prevention and Early Diagnosis. With a background in health psychology, Jo has worked for over 20 years in the field of cancer prevention, screening and early diagnosis. Her team's research aims to understand the acceptability, uptake and psychological impact of cancer screening. Her current work focuses on novel innovations including risk-stratification, self-sampling and the use of AI, as well as new screening technologies including the capsule sponge test for oesophageal cancer and multi-cancer early detection tests. Jo works closely with the UK national screening programmes and is a member of the UK National Screening Committee's Research and Methodology Group.




Professor Fiona Walter

Director, Wolfson Institute of Population Health

Fiona qualified in medicine at Cambridge University and St Thomas's Hospital, London, then trained as a general practitioner. In 2008 she launched the Cancer Research group in the University of Cambridge's Primary Care Unit. She was appointed Director of the Wolfson Institute of Population Health and Professor of Primary Care Cancer Research at Queen Mary University of London's Faculty of Medicine and Dentistry in April 2021.

Fiona's research focuses on primary care cancer diagnostics and patient pathways and experiences. She has won grants totalling more than £30M, and had more than 275 peer reviewed publications. Fiona co-led the CRUK-funded CanTest programme, with a strong focus on capacity development, and currently co-leads the CRUK-funded CanDetect programme on expediting detection of upper gastrointestinal cancers and the NIHR-funded Global Health Research Group AWACAN-ED, focussing on advancing early diagnosis of cancer in Southern Africa. She is a founder member of the CRUK EDD Research Committee.



Dr Victoria Whitelock

Health Research & Evaluation Manager, Cancer Research UK

Vicky has a PhD in health psychology and her background includes experimental, cross-sectional and longitudinal research to understand the determinants of health behaviours. Vicky has extensive experience designing, implementing and evaluating behavioural interventions. Vicky's work has spanned topics across cancer prevention (dietary behaviours in particular) and early diagnosis and screening. Her current work involves managing the Cancer Awareness Measure portfolio for Cancer Research UK, which includes an annual survey to monitor and track the UK public's attitudes, awareness and behaviours across key prevention, early diagnosis and screening topics. Vicky is also the CRUK lead for a project revalidating the Cancer Awareness Measure.



Professor Katriina Whitaker

Professor of Psychology and Lead for Cancer Care, University of Surrey

Katriina is a Chartered Psychologist and was made a Fellow of the British Psychological Society in 2017. Katriina's programme of research focuses on early diagnosis and cancer, with a particular interest in how people interact with the health care system and health inequalities. Katriina is an expert review panel member for Cancer Research UK's Early Diagnosis & Detection Trials, Behavioural Health System and Health Economics research panel and Tenovus Cancer Care Psychosocial Advisory Committee.



Phillipa Williams

Strategy Director, Claremont

Phillipa is Strategy Director at the behaviour change consultancy Claremont. Prior to joining Claremont, she spent ten years at the health charity Versus Arthritis, where she led the organisation's strategic communications, brand and social marketing activity. Her work was primarily focused on challenging the dismissal and apathy associated with arthritis; giving voice to, and amplifying, the experiences of people with arthritis to drive societal and system change. Prior to entering the charity sector, Phillipa worked on strategic communications and behaviour change campaigns at the agency, Fishburn Hedges. Her work spanned a wide range of social issues – from sexual health and stopping smoking to digital exclusion and promoting adult literacy.



Lorna Wills

Data and Research Analyst, Cancer Research UK

Lorna initially studied Biological Natural Sciences before completing a Master's degree in Population Health at University College London. She has worked as a data and research analyst in the partnership between the Cancer Intelligence team at Cancer Research UK and the National Disease Registration Service at NHS England for the past 4 years. Her work has largely focused on the early diagnosis and treatment of cancer. This has included calculating 10-year cancer survival estimates by stage at diagnosis and developing methodology to calculate the cost of initial surgery, chemotherapy, and radiotherapy treatment for cancer patients. She is currently working on an analysis of patients waiting over 104 days from urgent suspected cancer referral to starting cancer treatment.



Dr Pradeep Virdee

Statistician, University of Oxford


Pradeep is a statistician based in the Cancer Group at the University of Oxford's Nuffield Department of Primary Care Health Sciences. He provides statistical expertise on various projects, including the SYMPLIFY clinical trial, which assessed the diagnostic accuracy of the Galleri multi-cancer early detection test, and the BLOTTED project, which is investigating the role of repeat blood testing in primary care for earlier cancer detection and diagnosis.



Professor Christian Von Wagner

Professor of Behavioral Science, University College London

Christian is a Professor of Behavioural Science and leads the Behavioural science of Early Diagnosis of Cancer Group at UCL. Christian received his Bachelor of Science in Experimental Psychology from the University of Sussex and completed his PhD in Psychology at the University of York. His main research areas are the uptake and acceptability of Bowel Cancer screening and timely help seeking for cancer related symptoms. A central theme within his research are social inequalities in health care. He is a member of the Bowel Cancer Screening Research Advisory Group. He is a co-investigator of several large programme grants including the Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis at UCL, a CRUK programme grant on Risk Stratified Cancer Screening led by University of Edinburgh and QMUL and a NIHR Programme for Applied Health Research grant on the role of co-morbidities in spotting cancer symptoms.




Dr Yin Zhou

NIHR Academic Clinical Lecturer and GP, Queen Mary University


Yin has an interest in improving diagnostic safety and quality in primary care, in particular relating to early cancer diagnosis. Her work has focused on understanding missed diagnostic opportunities in bladder and renal cancer, as well as more broadly on examining inequalities in the cancer diagnostic process.

Early Career Researchers



Dr Adegoke Alabi

Adegoke is currently completing his training in Internal medicine with a view to undertaking higher speciality training in oncology. Simultaneously, he is pursuing a PhD in Applied Health Sciences funded by the Elphinstone scholarship scheme at the University of Aberdeen . His research focuses on the correlation between sociodemographic factors, such as rural living, and help-seeking behaviour for general and cancer symptoms.



Anietie Aliu

Anietie is a Post Graduate Researcher, a Health Sciences PhD student in the University of Surrey. Her research interest is on promoting equitable access and health outcomes particularly for the underserved ethnic minority populations. Her PhD focuses on understanding inequality in breast cancer screening for the women of Black African and Black Caribbean descent in the UK. She aims to co-design a user-friendly intervention that will improve breast screening experience for the Black British women.

Annette has identified knowledge gaps through her recently completed systematic review of screening barriers for Black women, the preliminary findings has been widely presented both as posters and oral talk in different academic and non-academic platforms.

Before her PhD, Annette has worked in the Healthcare industry as a registered Nurse and Public Health Professional for over two decades and has extensive experience in developing complex health interventions in community health and international health system consultancy.



Melissa Barlow

Melissa is a PhD student and Graduate Research Assistant at the University of Exeter. Her research interests are focused around advancing early cancer diagnosis in primary care. Her PhD project involves the development and validation of a robust lung cancer prediction model, aiming to effectively identify individuals at risk of undiagnosed lung cancer using readily available data from primary care records. In her role as a Graduate Research Assistant, Melissa is evaluating the efficacy of various blood tests for cancer detection in primary care with a specific focus on assessing their performance across diverse ethnic groups. Her work underscores her commitment to enhancing healthcare equity and improving outcomes for patients across different demographic backgrounds.



Jennifer Deane

Jennifer is a health services researcher within the Centre for Cancer and Institute of Population Health Sciences at Newcastle University. She is interested in the early diagnosis of cancer, in particular Head and Neck cancers, and in communication around cancer and the role of health literacy. She is currently working on projects around health literacy and early diagnosis of head and neck cancer, experiences of carers of people with pancreatic cancer and unravelling inequalities in lung cancer treatment receipt. She currently lives on the coast with her family and an aging sausage dog.



Dr Rebecca Dennison

Becky is a Research Associate in the Primary Care Unit, University of Cambridge. She has an interest in understanding public opinions towards novel strategies for cancer screening and early diagnosis. This includes risk stratification, acceptability, and communication needs. Becky uses both qualitative and quantitative research methods, and has expertise in community/citizens jury and discrete choice experiment methods. She has a background in natural sciences and completed her PhD in 2020, which described the development of type 2 diabetes in women with a history of gestational diabetes, and identified primary care-based approaches that can be used to reduce the risk of developing diabetes in this population.



Esra Erdem

Esra is a Researcher based at the Swansea Centre for Health Economics (SCHE), Swansea University. With an undergraduate degree (Ankara University, Turkey) and master's degree (Exeter University) in Economics, Esra recently completed my PhD at Aberystwyth University. Esra's PhD explored the global health and economic inequalities that the Covid-19 pandemic presented in developing countries. Esra's research not only helped to develop strong foundations in economic theory, quantitative analysis, and research methodologies, but has also helped to recognise the importance of improving healthcare pathways and inspired Esra to move into the field of health economics. At SCHE, Esra is working on the economic evaluation of the PROSTAD pathway, and involved in the design, conduct and analysis using economic modelling. Esra's particular interests lie in using economic methods to generate the evidence to guide decision making on the efficient allocation alongside equitable distribution of our scarce health and care resources to meet the needs of people with cancer and other complex health needs.



Bea Forder

Bea is a sixth-year medical student at the University of Oxford, starting work as a junior doctor in Surrey in August. Her initial research background from her pre-clinical years was in the molecular immunology of T-cell antigen discrimination, and for this and her performance in finals she won the British Society of Immunology Undergraduate of the Year Award. During later years of medical school, Bea has worked with Christiana Kartsonaki at the Nuffield Department of Population Health on risk prediction modelling and fine mapping of genes associated with gynaecological cancers. She is currently working with Robert Watson from the Fairfax group, based in the Weatherall Institute of Molecular Medicine, looking at single-cell RNA data from patients treated with immunotherapy for metastatic melanoma. Bea hopes to pursue a career as an academic oncologist, combining patient care with research into cancer immunology.



Emily Haworth

Emily completed her undergraduate degree in Psychology at Newcastle University achieving a First-class honours. She is now a research assistant in PHSI at Newcastle University who specialises in mixed methods research. Her work focuses on cancer diagnostic pathways, patient experience, and addressing cancer inequalities.



Dr Rhea Harewood

Rhea is a cancer epidemiologist and a Postdoctoral Research Fellow in the Department of Surgery and Cancer at Imperial College London. Her research interests lie in aetiological studies which investigate relationships between metabolites, and clinical and lifestyle factors, with colorectal cancer risk. Prior to her current role, Rhea completed a postdoctoral fellowship at the International Agency for Research in Cancer in Lyon, France. She also spent several years as a researcher at the London School of Hygiene and Tropical Medicine (LSHTM) examining drivers of inequality in cancer survival. Rhea has a PhD in Epidemiology from Imperial College London, an MSc in Public Health from LSHTM and a BSc in Chemistry from the University of the West Indies. She is an Associate Fellow of the Higher Education Academy in the UK and a member of the mentorship and outreach team of the Black in Cancer network.



Dr Owain Jones

Owain is an NHS GP and has an MPhil in Clinical Sciences. He is currently studying for a PhD in the use of Artificial Intelligence to facilitate the early diagnosis of skin cancer at the Department of Public Health & Primary Care, University of Cambridge. His current PhD studies include a qualitative study with patients, members of the public and healthcare professionals, and a discrete choice experiment; all evaluating the potential barriers and facilitators to the implementation of Artificial Intelligence technologies into the skin cancer diagnostic pathway.



Andres Tamm

Andres is a health data scientist and researcher working on applying machine learning methods to electronic health records to improve the understanding of cancer and cancer care. He is supervised by Dr Brian Nicholson at the Nuffield Department of Primary Care Health Sciences and by Professor Eva Morris at the Big Data Institute at the University of Oxford. As part of the Oxford University EPSRC Centre for Doctoral Training in Health Data Science, his recently submitted thesis investigated how the faecal immunochemical test can be combined with routinely collected data to increase its precision, developed lightweight text processing tools to extract cancer staging scores from free text clinical reports to facilitate cancer research, and explored methods of automatically clustering patient pathways to study variations in treatment.

People affected by cancer

We warmly welcome a group of people affected by cancer to the CRUK Early Diagnosis Conference. They will be scoring the posters on display and will be awarding prizes for those they think stand out. They will be on hand during the conference, and will be manning a CRUK patient stand, where they hope conference delegates stop by to discuss their research and health systems activity, and how insights from people affected have shaped, or could shape future activity.



Ada Agnes Agu

I am currently a master's student at the University of South Wales where I am studying Public Health. I also have a few years of clinical experience in Medicine. This, and losing a dear friend to cancer, is my driving force and motivation to be involved with the work of Cancer Research UK. This opportunity allows me to advocate for the importance of early diagnosis in cancer care. I can highlight the profound impact that timely detection can have on patients and their families by sharing personal narratives and insights gleaned from my experience as a caregiver. It is a great privilege to be part of the Early Diagnosis Conference this year and I am looking forward to gaining knowledge in the recent developments and research into early detection, treatment, and the awareness of any advanced treatments for cancer.



David Chuter

I was an oesophageal-gastric cancer patient, diagnosed and treated in 2006. As there was no patient-to-patient support available, I worked with my medical team to set up a patient support group at the end of 2006, which is still running monthly meetings.

My aim at the time was patient support but with so many new patients asking about research, I needed to learn more and get involved with research to help others make informed decisions about their treatment.

Oesophageal-Gastric cancer is survivable if diagnosed early enough, but sadly around 70% of patients go straight to palliative or end of life care as they're diagnosed at a late stage due to vague symptoms. Seeing younger patients coming to the support groups with early-onset cancer diagnosed at late stages more than ever before, it is simple to see that early diagnosis is crucial to ensure that treatment is effective and will save lives. We have to make sure we can diagnose early. There are so many factors explaining why it does not happen now. My motivation is to help in any way I can as a patient advocate, with my experience as a patient and that of my brother who was diagnosed too late.



Sue Duncombe

I was keen to utilise the skills and experience I had gained during my career to add value to organisations which were working to improve cancer outcomes. I became an active patient and public involvement (PPI) contributor to research nine years ago and I'm passionate about the value PPI can add to research.

My main area of interest is early detection and diagnosis. From family experiences I know the difference this can make; my mother died six months after a late diagnosis of gynae cancer, my husband died four years after his diagnosis of prostate cancer and my father survived both prostate and stomach cancer due to early diagnosis.

I've been appointed to numerous PPI roles. These have included being a lay member of various funding panels as well as supporting researchers with their funding submissions. I'm currently involved in various research projects with a range of academic institutions, charities, commercial organisations and the NIHR. My roles include being a lay member of steering and operational groups, as the PPI lead and as a member of PPI groups. I'm also involved in providing training to both PPI contributors and researchers.



Araya Gautam

I am a keen research lover and an advocate for under-represented minorities. I'm currently completing my examinations and hope to serve the community in research and health in future.

My interest for joining the Early Diagnosis Conference comes from my very own experience of working with ill people and having a very close loved one dying from cancer which had turned my life upside down. I'm looking forward to making connections and learning from the amazing people at this conference.



Jacqueline Jackson

I live in Prestwich, Greater Manchester. I'm married and have two adult children and I support my husband who is deaf and my elderly mother who lives in Bury.

Thirteen years ago, I was diagnosed with a few health conditions including Sjogrens Syndrome, Spinal Stenosis and Type 2 Diabetes. I was also diagnosed with dyslexia at the age of 49. These diagnoses explained many struggles I'd had whilst maintaining a full-time job and raising a family.

Three years ago, following a bowel cancer screening test, which came through the post, I was diagnosed with colon cancer. This came as total shock as I had no symptoms. I then had an operation removing half my bowel and six months of chemotherapy. This was extremely stressful at the time, given my other medical conditions, but I am pleased to say I am now cancer free at the moment.

I am now retired but remain registered as a Social worker, supporting others using my skills and knowledge in different roles as a School Governor, Church Safeguarding Coordinator, Chaperone and Patient Participant/Champion for my GP Surgery and Local Trust.

I also sit on the Cancer Research UK Cancer Insights Panel and feel I can make a positive contribution to people affected by cancer in future.



Margaret Johnson

Earlier and more timely diagnosis has been at the forefront of my involvement in cancer research owing to experiences of cancer in family members, from my son (aged 12) with T-ALL, two relatives diagnosed with terminal breast and bowel cancer, to my father diagnosed with lymphoma early enough to be successfully treated at the age of 80.

With further experience through close friends and family as well as support groups, I have been involved as PPI in cancer research for over 20 years with significant involvement in early diagnosis, including DISCOVERY and CanTest. I am a long-term member of the Cancer Research Advocate Forum (formerly NCRI Consumer Forum) and useMYdata and am a passionate advocate for clear, easily understood accessible information suitable for everyone. Involvement of patients/carers, with their unique cancer experiences at the centre of research, is vital, leading to far greater relevance to those it is meant to help. To continue to contribute usefully to research, it is necessary to keep abreast of developments and advances made through recent research, hence my wish to attend this early diagnosis conference.



Dave Kelsall

Early diagnosis is important to me because I wasn't diagnosed until stage 4, with mets in three major organs and in distant lymph nodes. I fully understood at the time (late 2013) how this significantly reduced my chances of a positive outcome. This late diagnosis created anxiety within my family and my GP felt guilty that, by following strict NICE guidance rather than her instincts, she may have significantly reduced my life expectancy.

As well as being a cancer patient, I've worked as a Clinical Information Officer in NHS provider and commissioner organisations and I understand the need to balance the competing pressures to be cost-effective and to avoid over-testing and over-scanning against the public's high expectations of an early diagnosis and associated benefits.

I've had the privilege of volunteering with CRUK in both the Health Awareness Roadshow team and as a Campaigns Ambassador – all of which has given an insight into some of the exciting research that's been underway in the past decade.



Rashmi Kumar

I'm an informal carer for a family member with long-term multiple health conditions, including cancer. I am responsible for managing everyday medical, health and care needs.

From a South Asian background, and living in area with multi-cultural and large socio-economic diverse communities, many experiencing and living with multiple health and social care challenges and deprivation, I'm engaging and helping many communities who are trying to manage everyday challenges working with local health care providers.

I'm Trustee of a large network of Patients Groups (50+ PPGs) working with GP Federations, Primary Care Providers (PCNs) and Integrated Health Care Board (ICBs).



Miranda Mikhelson

I am living testament to the need for early diagnosis and the big role that chance plays in current detection pathways. I was diagnosed with stage 2 invasive lobular breast cancer in 2020 at the start of the global pandemic when I was 45 years old. The cancer was only detected because I was on an early screening programme. I was only screened because both my older sisters had had their own breast cancer diagnoses (non-BRCA).

I have been lucky – but one of my sisters wasn't. Sadly, it was only once Linda's cancer had spread and ultimately took her life that I was referred to the early screening programme. I am keen to do whatever I can to improve early detection pathways and save other people from my sister's fate. And what about those people without siblings or unknown family history...?

All that being said, I truly feel that cancer hasn't been all bad news for me. Since my recovery I've developed a newfound appreciation for the here and now, and have made big changes in my life, including radically changing my career path to work for Macmillan Cancer Support in a Communications and Engagement role, promoting person-centred community-based care.



Charlotte Moss

I am a health policy professional and patient advocate. In 2016, my dad died from acute myeloid leukaemia less than three months after his diagnosis. In 2022, my mum was diagnosed with stage 3 bowel cancer; during her surgery recovery and chemotherapy, I was her primary carer while working full-time.

After my dad's death when I was 19, I began promoting the stem cell register and fundraising for cancer charities. Once I graduated from university, I interned at Anthony Nolan before joining the MHP Group's Health practice, where I managed policy, public affairs and patient advocacy projects for global, European and UK clients.

I am now the Industry Engagement and Policy Manager at the NHS Confederation. I design and deliver policy and engagement programmes with NHS members and partner organisations, as well as managing content for the 150+ sessions at NHS ConfedExpo.

In my spare time, I am a Campaigns Ambassador for Cancer Research UK, and continue to fundraise for other charities including Macmillan and Anthony Nolan. To date I have raised around £40,000 in memory of my dad.



Elaine Nangle

I'm Elaine, a mother of three from Reading, originally from Dublin, with a background in hedge funds. My academic journey includes a degree in Economics and Spanish from University College Dublin. However, my path shifted towards oncology and patient advocacy after being diagnosed with Invasive lobular carcinoma in 2020 at age 38.

Despite being young, active, and without a palpable lump, I delved into understanding this unique subset of breast cancer during lockdown. Faced with a lack of peer support in the UK, I founded the Facebook group "Linking Lobular Ladies" for patients with Lobular breast cancer, which now boasts over 1,000 members. Through this platform, I collaborated with fellow patient advocates to establish Lobular Breast Cancer UK, where I proudly serve as a Trustee. We work closely with healthcare professionals and researchers to advance trials, research, and improve information dissemination.

The distinct growth pattern of lobular breast cancer, often undetectable as a lump, complicates early detection, often leading to diagnosis at advanced stages. This drives my passion for emphasising the importance of early detection. In my professional capacity as a Macmillan Community Social Prescriber, I provide support to patients at any stage of their diagnosis, prioritising their social, emotional, financial, and mental well-being. It's an honour to contribute to their holistic care and guide them through their journey.




Stephen Rowley

I am looking forward to attending the CRUK Early Diagnosis Conference. I was treated for stage 3C colon cancer in 2015 and survived the onerous treatment. My brother Damon's cancer was advanced stage 4 and he died within six months. Both of us could have been caught earlier. Neither knew that we were at risk. Furthermore, my brother had been to the GP with clear symptoms but was not referred because he was 'too young' at 58 years.

Since then, I have become a patient advocate. Working with my local NHS health trust and Cancer Alliance initially, then nationally through CRUK, Bowel Cancer UK, BRUK and now internationally with Digestive Cancers Europe and Inspire 2 Live.

The most rewarding aspect of this role is to participate in research that will benefit future patients. Improving early diagnosis is an opportunity to reduce both the death and the suffering from colorectal cancers now, without waiting for new treatments. I am very pleased to be involved with early diagnosis and screening research as a PPI with UCL, Liverpool and Edinburgh Universities.



Denise Simpson-Bryan

I wanted to participate to contribute to a greater representation of ethnic voices in this space. My professional background is in software and having recently worked for an AI data analytics company, I'm very interested in how the medical community leverages data for diagnosis and treatment.

I was diagnosed with a Bowel NET (with metastasis to the liver) in 2018, and since conducting a lot of personal research, my concern has been that there isn't enough input from patients from minority backgrounds. This can fundamentally have an impact on the diagnosis timeline, suggested treatment pathways, and even responses to treatment and experienced side effects.

I currently sit on two patient involvement panels; for Integrative Cancer Epidemiology Programme (ICEP) run by University of Bristol and CRUK; and the Centre for Drug Development (CDD).

I want to be part of the solution - I have two children and I want to be able to say that I did everything I could do to contribute to a dialogue that promotes the inclusion of their voices and input into any research that improves the diagnosis and treatment for all.

Early diagnosis research posters

Implementation and optimisation of screening

No.	Author	Title
1	Dr Ananya Malhotra	Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data
2	Emily Rayner	Understanding barriers to cancer awareness and screening uptake among 'White Other' residents of North East London
3	Dr Sowmiya Moorthie	Systems based analysis exploring the potential to implement risk stratified bowel cancer screening in England
4	Obi Onyiah	Cancer Awareness in the Charedi Jewish population
5	Sharon Power	The impact of patient-reported factors of endoscopic screening experience and the effect on attendance at future examinations and distal CRC incidence
6	Dr Smitha Nathan	Uptake of a Targeted Lung Health Check service in South East London at baseline October 2022 – January 2023

Supporting timely help-seeking presentation by the public

No.	Author	Title
7	Dr Afrodita Marcu	Symptom appraisal and help-seeking before a cancer diagnosis during pregnancy: a qualitative study
8	Dr Maddy Young	A Third Sector Campaign to Increase Symptom Awareness of Oesophageal and Stomach Cancer in Wales
9	Dr Savita Shanbhag	Awareness of lung cancer symptoms amongst the adult population in West Wales: Insights from the LUMEN project
10	Sherrice Weekes	You Need to Know – Womb Cancer Awareness
11	Samantha Lewis	Understanding barriers and enablers to facilitate earlier diagnosis of Breast and Prostate Cancer amongst our Black African and Black Caribbean community in South-East London

Optimising the referral journey from primary to secondary care

No.	Author	Title
12	Eliya Abedi	AI-based Detection of Colorectal Cancer in Primary care
13	Dr Meena Rafiq	Predictive value of abnormal blood tests for detecting cancer in primary care patients with non-specific abdominal symptoms
14	Dr Jayne Digby	Increasing the faecal haemoglobin threshold for referral may not adversely affect the outcome of patients in primary care with new bowel symptoms: an observational study
15	Dr Becky White	Improving the assessment of cancer risk in patients presenting in primary care with fatigue: results of three population-based cohort studies
16	Dr Christina Derksen	Computerised clinical decision support systems (CDSS) for the detection of disease in primary care: Systematic review and recommendations for disease detection tools
17	Judith Strachan	GP referral rate and clinical outcome of patients according to FIT result
18	Nadine Zakkak	The stage distribution of cancers by presenting symptom
19	Dr Savita Shanbhag	Faecal Immunochemical Testing (FIT) in primary care – an innovative approach to streamline cancer referrals
20	Freya Pollington	Risk of oesophago-gastric cancer in patients presenting to their GP with potential symptoms and symptomatically similar diseases
21	Dr Claire Friedemann Smith	General practitioner referrals to fast-track investigations for symptoms that could be indicative of cancer: A systematic review and meta-analysis of use and clinical outcomes
22	Kiana K Collins	Prostate specific antigen (PSA) retesting intervals and trends in England: A retrospective cohort study of over 10 million patients between 2000 – 2020
23	Sheba Ziyenge	Trends and sociodemographic variation in primary care consultations and urgent referrals for potential cancer symptoms: 2019 to 2023
24	Anam Ayaz-Shah	General Practitioner acceptability and feasibility for using point of care tests to detect cancer in primary care

Improving pathways and service models to support timely cancer diagnosis

No.	Author	Title
25	Dr Elinor Nemlander	New technology and working methods to improve healthcare for suspected malignant skin lesions: implementation of teledermatoscopy in comprehensive healthcare
26	Dr Heather Wilkes	Development and Evaluation of an all Wales National RDC Service for Earlier Cancer Diagnosis
27	Laura Standen	Can cognitive function tests discriminate between patients with and without glioma prior to treatment? A systematic review
28	Dr Shaheena Sadiq	Rapid Diagnosis Neck Lump Clinic: A Novel Patient-centred Approach to Diagnosing Neck Lumps
29	Dr Katie Jones	A Rapid Diagnostic Pathway for Prostate Cancer: Exploring Patient Experience
30	Dr Beth Russell	Evaluation of rapid diagnostic clinics as an alternative route for patients with non-site-specific symptoms
31	Maria J Monroy-Iglesias	Efficiency and Timeliness of Rapid Diagnostic Clinics: A Six-Month Evaluation in Southeast London
32	Hussain Ibrahim	The ColoCap study: determining the diagnostic accuracy of colon capsule endoscopy compared to standard colonoscopy in patients at risk of colorectal disease
33	Dr Maria Qurashi	Clinicians' barriers to implementing hepatocellular carcinoma (HCC) surveillance
34	Lucy McLaughlin	Methodological framework for commissioning a non-specific symptoms (NSS) pathway in North Central London
35	Dr Richard Gallon	Enhanced MSI testing for Lynch syndrome screening and urogenital tumour surveillance
36	Georgina Gardner	RCT of Contrast enhanced and AI assisted colonoscopy vs standard care in Colorectal cancer screening for earlier detection of colorectal cancer and reduction in interval cancers
37	Soumya Arun	From Code to Clinic - Systematic scoping review of external validation studies of artificial intelligence modalities for the digital pathology-based diagnosis of lung cancer
38	Emily Haworth	Experiences of capsule endoscopy among patients with suspected bowel cancer: preliminary findings from the Newcastle ENDOPREM-capsule qualitative study
39	Dr Sarah Chowienczyk	CanSEER – creating a digital toolkit to track waiting times for suspected cancer investigations and cancer treatment in England

40	Dr Tim CH Hoogenboom	The Impact of Community-Based Teledermatology Model on Cost-Effectiveness and Efficiency in Cancer Diagnosis: Implementation of Pathpoint eDerma Platform in the NHS
41	Dr Dilraj Kalsi	The role for Artificial Intelligence as a Medical Device (AIaMD) in pre-referral skin cancer pathways: Evaluation approach and early findings
42	Dr Carole Cummins	Transforming Ovarian Cancer diagnostic pathways: An effectiveness-implementation study of a novel biomarker based (ROMA algorithm), threshold driven integrated community-primary-secondary-tertiary care pathway for earlier ovarian cancer diagnosis: a hybrid Type 1 effectiveness-implementation project

Translation of innovation – New diagnostic tests and tools supporting the earlier detection of cancer

No.	Author	Title
43	Rosario Luxardo	Budget impact analysis of using a novel urine biomarker test to support early diagnosis of pancreatic ductal adenocarcinoma
44	Stefanie Bonfield	Exploring experiences of and preferences for early cancer detection tests among individuals at risk of socioeconomic disadvantage: a qualitative interview study
45	Edwina Burke	Understanding circulating tumour cell clusters in prostate cancer
46	Dr Laura Marlow	Intention to have blood-based multi-cancer early detection (MCED) screening – a cross-sectional population-based survey in England
47	Dr Tyler S. Saunders	Examining the performance of diagnostic risk prediction models and tools for upper gastro-intestinal cancers: A systematic review
48	Ian Lowenhoff	Clinical Referral to the NHS Following Multi-Cancer Early Detection Test Results from the NHS-Galleri Trial
49	Dr Yue Wu	Validation of the Biomarker Toolkit: Diagnostic Colorectal Cancer Biomarkers
50	Dr Nigel Sansom	The PinPoint Test: an AI-driven blood test to streamline and accelerate the patient journey to diagnosis and treatment
51	Nerissa Thomas	Development of a label-free liquid biopsy for early-stage cancer detection
52	Ashley Jackson	Positive MCED test results associated with later cancer diagnosis in participants in the SYMPLIFY study

53	Dr Pradeep Virdee	Enhancing the diagnostic performance of a multi-cancer early detection test with patient characteristics, symptoms, and standard laboratory test results
54	Dr John Buckell	Preferences for Multi-Cancer Early Detection (MCED) in primary care: Discrete choice experiments in four stakeholder groups in England


Cross-cutting

No.	Author	Title
55	Dr Mairi Whiston	Improving diagnosis of myeloma: a multidisciplinary approach
56	Claire Price	A protocol to validate an algorithm for the early diagnosis of pancreatic cancer using UK primary care data
57	Andrew Prentice	Creating an evidence base for Public Health interventions for Bowel Cancer Screening Awareness utilising a CRC diagnosis all pathways audit
58	Dr Sharon Tate	Ovarian and renal cancer health improvement iDeas (ORCHID) project
59	Dr Pilar Acedo	Advancing Early Cancer Diagnosis: The ADEPTS Study for pancreatic cancer and other pancreaticobiliary diseases
60	Dr Ruth Norris	Routes to diagnosis in lung cancer– do socio-demographics matter? An English population-based study
61	Dr Silvana Debernardi	Large prospective observational study for validation of urinary biomarker test for the earlier detection of pancreatic adenocarcinoma
62	Marta Berglund	Pre-diagnostic healthcare in lung cancer patients diagnosed as an emergency or through other diagnostic routes: A cohort study using linked GP and hospital data in England
63	Nadine Zakkak	Risk of cancer incidence and cancer mortality among patients with new-onset atrial fibrillation: a population-based matched cohort study
64	Dr Luke Robles	Exploring the role of interim non-cancer diagnoses in missed opportunities for detecting cancer: a qualitative study of health care providers in primary care
65	Dr Natalia Calanzani	A systematic scoping review of cancer outcomes in rural and remote Scotland, with a focus on early diagnosis
66	Dr Emily Scott	Why the Emergency? Improving Early Cancer Detection in the East of England

Conference planning team


The Cancer Research UK Early Diagnosis Conference was organised by the Evidence & Implementation department at CRUK. The conference is planned and developed with contributions from a number of CRUK teams, who have been working collaboratively over the past year to ensure a smooth delivery and a meaningful experience for all attendees.

Conference Lead



Sam Harrison
Head of Strategic Evidence

Programme Lead



Lyndsy Ambler
Senior Strategic Evidence Manager


Supported by: James Baker, Lucy Ironmonger, Sowmiya Moorthie, Kirstie Osborne, Hope Walters, Joanna Janus and Talisa Quallo

Event and Technical Support



Katie Bevan
Senior Area Events Manager

Operational and Logistics Leads



Laura Handy
Senior Strategic Evidence and Engagement Manager



Hannah Taylor
Strategic Evidence and Engagement Officer



Jaimee Kerven
Strategic Evidence and Engagement Manager

Supported by: Naomi Bemment, Duha Gheasuddin, Katie Nania and Tahmina Nusrat

Thank you for attending Cancer Research UK's Early Diagnosis Conference 2024.
We hope you enjoyed it.

The Early Diagnosis Conference team would value your feedback, which will help us improve future events. **Please fill in the form provided at the end of the event to share your feedback or fill in the online form [here](#).**

If you would like to share more detailed feedback, please contact
EDconference@cancer.org.uk

For information on future early diagnosis events, please follow us on X (previously known as Twitter) at **@CRUKHCPs**

Produced by Cancer Research UK, May 2024

Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247).
© Cancer Research UK (2024)



**Together we are
beating cancer**